Anixa Biosciences to Showcase Cancer Vaccine and CAR-T Progress at Nasdaq Summit
Event summary
- Anixa Biosciences CEO Dr. Amit Kumar to present at Nasdaq & LD Micro Inaugural SF Summit on September 9, 2026.
- Presentation to highlight Phase 1 trial results for breast cancer vaccine and ongoing Phase 1 trial for CAR-T ovarian cancer therapy.
- Breast cancer vaccine trial met all primary endpoints, with Phase 2 plans to be discussed.
- CAR-T therapy for ovarian cancer shows encouraging survival data with no dose-limited toxicities observed.
- Event includes breakout sessions for direct investor engagement.
The big picture
Anixa Biosciences is positioning itself at the forefront of cancer immunotherapy, with strategic collaborations with Moffitt Cancer Center and Cleveland Clinic. The company's focus on both therapeutic and prophylactic cancer vaccines, alongside its innovative CAR-T technology, aligns with the broader industry shift towards personalized and targeted cancer treatments. The upcoming presentation at the Nasdaq summit provides a critical platform to showcase these advancements to institutional investors.
What we're watching
- Clinical Progress
- How the Phase 1 breast cancer vaccine results will translate into Phase 2 trial design and success.
- Market Positioning
- Whether Anixa can leverage recent melanoma vaccine success to bolster investor confidence in its own vaccine program.
- Execution Risk
- The pace at which Anixa can advance its CAR-T therapy through clinical trials given the encouraging early data.
Related topics